TG Therapeutics has announced that it has received an accelerated FDA approval for Ukoniq (umbralisib) used to treat for two types of blood cancer.
Adam Waldman, TG Therapeutics CCO, said they will release a new, once-daily oral medication next week at a cost of $15,900 for a 30-day supply.
Click here to read the entire article.